Table 4.
Survival models for patients with COVID-19-associated IFDs.
| Variable | IC | PMD |
|---|---|---|
| Age > 65 years | 2.84 (1.34–6.02) | 1.76 (0.75–4.10) |
| SOFA score > 12 | 3.64 (1.46–9.05) | 0.76 (0.097–5.99) |
| Charlson score > 2 | 1.72 (0.81–3.65) | 1.74 (0.70–4.32) |
| Primary treatment | ||
| Echinocandin | 0.44 (0.20–0.94) | 1.68 (0.56–5.075) |
| Fluconazole | 0.92 (0.39–2.17) | NA |
| Extended-spectrum azole | NA | 0.23 (0.093–0.57) |
| Cox proportional hazards model | ||
| Age > 65 years | 3.52 (1.26–9.77) | NA |
| SOFA score > 12 | 7.37 (2.38–22.77) | NA |
| Echinocandin | 0.26 (0.07–0.91) | NA |
SOFA: sequential organ failure assessment; IC: invasive candidiasis; PMD: pulmonary mold disease; NA: not applicable.